These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

505 related articles for article (PubMed ID: 23620211)

  • 1. Dabigatran for the prevention of stroke and systemic embolism in atrial fibrillation: A NICE single technology appraisal.
    Faria R; Spackman E; Burch J; Corbacho B; Todd D; Pepper C; Woolacott N; Palmer S
    Pharmacoeconomics; 2013 Jul; 31(7):551-62. PubMed ID: 23620211
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-effectiveness of dabigatran etexilate for the prevention of stroke and systemic embolism in UK patients with atrial fibrillation.
    Kansal AR; Sorensen SV; Gani R; Robinson P; Pan F; Plumb JM; Cowie MR
    Heart; 2012 Apr; 98(7):573-8. PubMed ID: 22422743
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dabigatran etexilate for the prevention of venous thromboembolism in patients undergoing elective hip or knee surgery: a NICE single technology appraisal.
    Holmes M; Carroll C; Papaioannou D
    Pharmacoeconomics; 2012 Feb; 30(2):137-46. PubMed ID: 22185183
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A comparative analysis of models used to evaluate the cost-effectiveness of dabigatran versus warfarin for the prevention of stroke in atrial fibrillation.
    Sorensen SV; Peng S; Monz BU; Bradley-Kennedy C; Kansal AR
    Pharmacoeconomics; 2013 Jul; 31(7):589-604. PubMed ID: 23615895
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Economic appraisal of dabigatran as first-line therapy for stroke prevention in atrial fibrillation.
    Bergh M; Marais CA; Miller-Jansön H; Salie F; Stander MP
    S Afr Med J; 2013 Feb; 103(4):241-5. PubMed ID: 23547700
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ipilimumab for Previously Untreated Unresectable Malignant Melanoma: A Critique of the Evidence.
    Giannopoulou C; Sideris E; Wade R; Moe-Byrne T; Eastwood A; McKenna C
    Pharmacoeconomics; 2015 Dec; 33(12):1269-79. PubMed ID: 26043718
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-effectiveness of dabigatran versus vitamin K antagonists for the prevention of stroke in patients with atrial fibrillation: a French payer perspective.
    Chevalier J; Delaitre O; Hammès F; de Pouvourville G
    Arch Cardiovasc Dis; 2014; 107(6-7):381-90. PubMed ID: 24973113
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Stroke prevention in patients with atrial fibrillation in France: comparative cost-effectiveness of new oral anticoagulants (apixaban, dabigatran, and rivaroxaban), warfarin, and aspirin.
    Lanitis T; Cotté FE; Gaudin AF; Kachaner I; Kongnakorn T; Durand-Zaleski I
    J Med Econ; 2014 Aug; 17(8):587-98. PubMed ID: 24831811
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dabigatran etexilate: a pharmacoeconomic review of its use in the prevention of stroke and systemic embolism in patients with atrial fibrillation.
    McKeage K
    Pharmacoeconomics; 2012 Sep; 30(9):841-55. PubMed ID: 22734683
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dabigatran versus rivaroxaban for the prevention of stroke and systemic embolism in atrial fibrillation in Canada. Comparative efficacy and cost-effectiveness.
    Kansal AR; Sharma M; Bradley-Kennedy C; Clemens A; Monz BU; Peng S; Roskell N; Sorensen SV
    Thromb Haemost; 2012 Oct; 108(4):672-82. PubMed ID: 22898892
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-effectiveness of dabigatran etexilate for the prevention of stroke and systemic embolism in atrial fibrillation in Taiwan.
    Chang CH; Yang YH; Chen JH; Lin LJ
    Thromb Res; 2014 May; 133(5):782-9. PubMed ID: 24642004
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-effectiveness of dabigatran etexilate for the prevention of stroke and systemic embolism in atrial fibrillation: a Canadian payer perspective.
    Sorensen SV; Kansal AR; Connolly S; Peng S; Linnehan J; Bradley-Kennedy C; Plumb JM
    Thromb Haemost; 2011 May; 105(5):908-19. PubMed ID: 21431243
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-effectiveness of dabigatran compared with warfarin for stroke prevention in atrial fibrillation.
    Freeman JV; Zhu RP; Owens DK; Garber AM; Hutton DW; Go AS; Wang PJ; Turakhia MP
    Ann Intern Med; 2011 Jan; 154(1):1-11. PubMed ID: 21041570
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-effectiveness of dabigatran compared with warfarin for stroke prevention in patients with atrial fibrillation and prior stroke or transient ischemic attack.
    Kamel H; Johnston SC; Easton JD; Kim AS
    Stroke; 2012 Mar; 43(3):881-3. PubMed ID: 22308255
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dronedarone for the treatment of atrial fibrillation: a NICE single technology appraisal.
    McKenna C; Maund E; Sarowar M; Fox D; Stevenson M; Pepper C; Woolacott N; Palmer S
    Pharmacoeconomics; 2012 Jan; 30(1):35-46. PubMed ID: 22136303
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-effectiveness of dabigatran etexilate for stroke prevention in non-valvular atrial fibrillation. Applying RE-LY to clinical practice in Denmark.
    Langkilde LK; Bergholdt Asmussen M; Overgaard M
    J Med Econ; 2012; 15(4):695-703. PubMed ID: 22397590
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Direct thrombin inhibitors versus vitamin K antagonists for preventing cerebral or systemic embolism in people with non-valvular atrial fibrillation.
    Salazar CA; del Aguila D; Cordova EG
    Cochrane Database Syst Rev; 2014 Mar; 2014(3):CD009893. PubMed ID: 24677203
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Cost-effectiveness of apixaban compared to other new oral anticoagulants in patients with non-valvular atrial fibrillation].
    Rudakova AV; Tatarskiĭ BA
    Kardiologiia; 2014; 54(7):43-52. PubMed ID: 25177813
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-effectiveness of dabigatran etexilate in the prevention of stroke and systemic embolism in patients with atrial fibrillation in Belgium.
    Wouters H; Thijs V; Annemans L
    J Med Econ; 2013; 16(3):407-14. PubMed ID: 23320796
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Apixaban, dabigatran, and rivaroxaban versus warfarin for stroke prevention in non-valvular atrial fibrillation: a cost-effectiveness analysis.
    Rognoni C; Marchetti M; Quaglini S; Liberato NL
    Clin Drug Investig; 2014 Jan; 34(1):9-17. PubMed ID: 24135964
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.